Literature DB >> 17854433

Assessing the impact of censoring of costs and effects on health-care decision-making: an example using the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study.

Elisabeth Fenwick1, Deborah A Marshall, Gordon Blackhouse, Humberto Vidaillet, April Slee, Lynn Shemanski, Adrian R Levy.   

Abstract

OBJECTIVES: Losses to follow-up and administrative censoring can cloud the interpretation of trial-based economic evaluations. A number of investigators have examined the impact of different levels of adjustment for censoring, including nonadjustment, adjustment of effects only, and adjustment for both costs and effects. Nevertheless, there is a lack of research on the impact of censoring on decision-making. The objective of this study was to estimate the impact of adjustment for censoring on the interpretation of cost-effectiveness results and expected value of perfect information (EVPI), using a trial-based analysis that compared rate- and rhythm-control treatments for persons with atrial fibrillation.
METHODS: Three different levels of adjustment for censoring were examined: no censoring of cost and effects, censoring of effects only, and censoring of both costs and effects. In each case, bootstrapping was used to estimate the uncertainty incosts and effects, and the EVPI was calculated to determine the potential worth of further research.
RESULTS: Censoring did not impact the adoption decision. Nevertheless, this was not the case for the decision uncertainty or the EVPI. For a threshold of $50,000 per life-year, the EVPI varied between $626,000 (partial censoring) to $117 million (full censoring) for the eligible US population.
CONCLUSIONS: The level of adjustment for censoring in trial-based cost-effectiveness analyses can impact on the decisions to fund a new technology and to devote resources for further research. Only when censoring is taken into account for both costs and effects are these decisions appropriately addressed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17854433     DOI: 10.1111/j.1524-4733.2007.00254.x

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  6 in total

Review 1.  A systematic and critical review of the evolving methods and applications of value of information in academia and practice.

Authors:  Lotte Steuten; Gijs van de Wetering; Karin Groothuis-Oudshoorn; Valesca Retèl
Journal:  Pharmacoeconomics       Date:  2013-01       Impact factor: 4.981

2.  Cost-effectiveness analysis: a proposal of new reporting standards in statistical analysis.

Authors:  Heejung Bang; Hongwei Zhao
Journal:  J Biopharm Stat       Date:  2014       Impact factor: 1.051

3.  SF-6D and EQ-5D result in widely divergent incremental cost-effectiveness ratios in a clinical trial of older women: implications for health policy decisions.

Authors:  J C Davis; T Liu-Ambrose; K M Khan; M C Robertson; C A Marra
Journal:  Osteoporos Int       Date:  2011-09-10       Impact factor: 4.507

Review 4.  Cost effectiveness of antiarrhythmic medications in patients suffering from atrial fibrillation.

Authors:  Bernd Brüggenjürgen; Stefan Kohler; Nadja Ezzat; Thomas Reinhold; Stefan N Willich
Journal:  Pharmacoeconomics       Date:  2013-03       Impact factor: 4.981

5.  Protocol for an economic evaluation alongside the University Health Network Whiplash Intervention Trial: cost-effectiveness of education and activation, a rehabilitation program, and the legislated standard of care for acute whiplash injury in Ontario.

Authors:  Gabrielle van der Velde; Pierre Côté; Ahmed M Bayoumi; J David Cassidy; Eleanor Boyle; Heather M Shearer; Maja Stupar; Craig Jacobs; Carlo Ammendolia; Simon Carette; Maurits van Tulder
Journal:  BMC Public Health       Date:  2011-07-27       Impact factor: 3.295

6.  Developing appropriate methods for cost-effectiveness analysis of cluster randomized trials.

Authors:  Manuel Gomes; Edmond S-W Ng; Richard Grieve; Richard Nixon; James Carpenter; Simon G Thompson
Journal:  Med Decis Making       Date:  2011-10-19       Impact factor: 2.583

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.